Hoth Therapeutics rises on positive preclinical study results for Alzheimer's drug
17/09/2024 14:50
** Hoth Therapeutics' shares HOTH.O rise 15% to $1.17 in
early trade
** Co announces positive preclinical study results for their
HT-ALZ investigational Alzheimer's drug
** The study data shows improved cognitive function among
the Alzheimer's model mice treated with HT-ALZ
** HOTH notes early observations point to a potential link
between reduced reactive astrocytic activity in parts of the
brain and improved cognitive function
** Up to Monday's close, stock had fallen ~30% YTD
(Reporting by Neil J Kanatt in Bengaluru)
((Neil.JKanatt@thomsonreuters.com;))
Recent news on Rocket One
See all newsBrief: Rocket One Signs AI Chip Development Agreement Targeting Ultra-Low-Power Magnetic Computing
Brief: Rocket One Signs Agreement To Advance Nanomagnetic Ai Chip Technology And Device Prototyping
Brief: Rocket One Signs Patent License Agreement With U.S. Air Force For Technology Designed To Capture And Neutralize Hostile Drones
Brief: Rocket One To Buy 100% Ownership Of Tracer Drone Technologies
Brief: Rocket One And Nasa Reach Agreement To Advance Space Ai Technology